Mayo Clinic cornea experts said long-term, low-dose valacyclovir can reduce keratitis, iritis, and other ocular complications caused by herpes zoster ophthalmicus.
This therapeutic approach is significant because it aims to minimize permanent eye damage and chronic symptoms in patients whose shingles infection has affected the eye. By managing the virus over a longer period, clinicians may prevent the severe inflammatory responses that often lead to vision loss.
Dr. Keith Baratz and Dr. Elisabeth Cohen said these findings during a Mayo Clinic Ophthalmology Podcast. The experts focused on how the antiviral medication helps manage sequelae—the secondary conditions that follow the initial infection—specifically within the cornea and iris.
Herpes zoster ophthalmicus occurs when the varicella-zoster virus reactivates in the ophthalmic branch of the trigeminal nerve. This can lead to painful rashes and internal eye inflammation. While acute treatment is standard, the experts said the benefits of a sustained, low-dose regimen to maintain ocular stability.
The scale of the issue is substantial in the U.S. Approximately one million new shingles cases occur in the United States each year [1]. Of those cases, about 80,000 develop vision-related side effects [2].
The discussion highlighted that the goal of this long-term strategy is to reduce the frequency and severity of recurrences. By suppressing the virus, the treatment helps prevent the cycle of inflammation and scarring that characterizes chronic keratitis and iritis. This proactive management allows patients to maintain better visual acuity and reduces the need for aggressive steroid treatments that can carry their own risks.
“Long-term, low-dose valacyclovir can reduce keratitis, iritis, and other ocular complications.”
The shift toward long-term, low-dose antiviral therapy represents a move from reactive treatment to preventative maintenance for herpes zoster ophthalmicus. By reducing the incidence of keratitis and iritis, this approach may lower the overall burden of permanent vision impairment for thousands of patients annually, shifting the clinical focus toward long-term ocular stability rather than just acute symptom relief.
